Latest News

Roche in take-over deal with GenMark Diagnostics

© Roche AG


by tg

Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.

The US$1.8bn cash merger – US$ 24.05 per share –  is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s unaffected closing share price on February 10, 2021.

GenMark’s multiplex PCR panel testing portfolio will complement Roche’s current molecular diagnostics portfolio. According to Thomas Schinecker, CEO Roche Diagnostics, GenMarl’s panel testing "provides faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays."

Utilizing GenMark’s point-of-care eSensor detection technology, GenMark’s eSensor XT-8 and ePlex systems are designed to address a broad range of infectious disease testing needs, including respiratory, bloodstream and gastrointestinal infections.

Evonetix extends Series B financing to US$54m

According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

New partnerships push InDevR for Series B financing

Investments into InDevR, Inc. came from New York-based Adjuvant Capital ($4m) and French bioMèrieux SA ($5m), which will enable the commercial...

BioNTech bags Instadeep for £562m

According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

Germany’s Curevac offers common shares

In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

Roche withdraws checkpoint blocker from the market

Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Vésale Bioscience wins R&D grant

Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...

AMsilk scaling up through Evonik collaboration

Just one week after AMSilk inked a collaboration agreement on protein engineering of its silk protein to target new applications with Brain Biotech...